AXIOS October 31, 2023
Shawna Chen

The push to use psychedelics as treatment for veterans with PTSD is gaining momentum across the country — and the Bay Area is taking the lead.

Why it matters: Studies show that MDMAs reduce PTSD symptoms and functional impairment. Advocates are working to secure FDA approval of its use in a bid to more effectively tackle the suicide epidemic among veterans.

State of play: Veterans Affairs Palo Alto is gearing up to recruit and screen participants for its own clinical trials with MDMA-assisted therapy, according to Stanford psychiatry professor Trisha Suppes, who is overseeing the research.

  • Under current protocol, patients are administered the compound three times over a 12- to 14-week period in a controlled, supervised setting with therapists.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Patient / Consumer, Provider, VA / DoD
The Evolution of eConsent Management for Mental Health, Substance Use Disorders Data
Buprenorphine Prescribing Gaining Ground at Community Health Centers
Addiction Provider Hope River Ranch Raises $16.7M
Most Americans say mental health issues get worse treatment than physical ones
Private Equity Owns 6.2% of Mental Health, 7.1% of Addiction Treatment Facilities

Share This Article